Ann Arbor, Michigan: RetroSense Therapeutics, a privately-held biotechnology company developing novel gene therapies for vision restoration, announced that Allergan plc has acquired all assets related to its lead development program in an all-cash transaction. RetroSense’s RST-001 program employs a photosensitivity gene to restore vision in patients suffering from blindness due to retinitis pigmentosa (RP) and advanced dry age-related macular degeneration. Neither of these conditions have FDA-approved treatments to improve or restore vision.
“There are some great things going on at TSRL,” said former RetroSense CEO Sean Ainsworth. “It was a nice opportunity to work and be co-located with like-minded, driven companies that want to have a positive impact on human health.”
TSRL, Inc. worked with Sean to provide business support and office space for RetroSense as the company expanded operations. Recent milestones for the company included receiving an Orphan Drug Designation for RP in 2014, an IND approval in August 2015 and initiation of a Phase I/IIa clinical trial in March 2016. RetroSense was founded in 2009, securing exclusive, worldwide rights to the optogenetics technology pioneered at Michigan’s Wayne State University and Pennsylvania’s Salus University.
About TSRL, Inc:
TSRL, Inc. is a privately-held, anti-infectives pharmaceutical accelerator focused on the preclinical development of investigator-initiated drug therapy concepts. More information about TSRL, Inc. is available on the company website www.tsrlinc.com or can be requested by contacting Andrew Hertig, Business Development, 734-663-4233 x224, email@example.com.